SAN FRANCISCO, May 08, 2023 (GLOBE NEWSWIRE) -- AltruBio Inc. (“AltruBio” or “the Company”), a clinical stage biotech company dedicated to the development of novel therapeutics for the treatment of ...
Palisade Bio's PALI-2108 will be presented at Digestive Disease Week 2025, highlighting its potential in ulcerative colitis treatment. Palisade Bio's lead program PALI-2108 has been recognized, being ...
HAMBURG, Germany, April 24, 2025--(BUSINESS WIRE)--Topas Therapeutics today announced that it will present clinical Phase 2a data on its lead candidate, TPM502, in celiac disease patients at the ...
WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class ...
Glasgow, Scotland - 28 April 2025. EnteroBiotix Limited ('EnteroBiotix'), a biopharmaceutical company developing best-in-class therapies for gut health, today announced that data from its Phase 2a ...
Evoke Pharma, Inc. announced that an abstract comparing the incidence of tardive dyskinesia (TD) in patients undergoing continuous versus intermittent oral metoclopramide treatment has been accepted ...
In a recent press release, The Endoscopy Division of FUJIFILM Medical Systems U.S.A., Inc. announced that they will host an educational session by Double-Balloon method pioneer Hironori Yamamoto, M.D.
EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week® 2025 Glasgow, Scotland - 28 April 2025. EnteroBiotix Limited ('EnteroBiotix'), a biopharmaceutical company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback